Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization
Public ClinicalTrials.gov record NCT00436553. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 24-month Randomized, Double-masked, Controlled, Multicenter, Phase IIIB Study Assessing Safety and Efficacy of Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab Versus Ranibizumab Monotherapy in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study evaluated the effect of combination therapy with verteporfin photodynamic therapy and ranibizumab on visual acuity and anatomic outcomes compared to ranibizumab monotherapy and the durability of response observed in patients with choroidal neovascularization secondary to age-related macular degeneration.
Study identification
- NCT ID
- NCT00436553
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 321 participants
Conditions and interventions
Conditions
Interventions
- Verteporfin Photodynamic Therapy Drug
- Ranibizumab Drug
- Verteporfin Placebo Drug
- Ranibizumab Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 2007 (Type not available)
- Primary completion
- Oct 2009 (Actual)
- Completion
- Oct 2009 (Actual)
- Last update posted
- Apr 19, 2011
2007 – 2009
United States locations
- U.S. sites
- 36
- U.S. states
- 20
- U.S. cities
- 36
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Tucson | Arizona | 85704 | — |
| Novartis Investigative Site | Beverly Hills | California | 90211 | — |
| Novartis Investigative Site | Oakland | California | 94609 | — |
| Novartis Investigative Site | Pasadena | California | 91105-3153 | — |
| Novartis Investigative Site | Sacramento | California | 95819 | — |
| West Coast Retina Medical Group Inc. - 185 Berry St. Suite 130 | San Francisco | California | 94107 | — |
| Novartis Investigative Site | Santa Ana | California | 92705 | — |
| Novartis Investigative Site | Denver | Colorado | 80210 | — |
| Novartis Investigative Site | ‘Aiea | Hawaii | 96701 | — |
| Novartis Investigative Site | Iowa City | Iowa | 52242 | — |
| Novartis Investigative Site | Wichita | Kansas | 67214 | — |
| Novartis Investigative Site | Lexington | Kentucky | 40509 | — |
| Novartis Investigative Site | Paducah | Kentucky | 42001 | — |
| Novartis Investigative Site | Baltimore | Maryland | 21205 | — |
| Novartis Investigative Site | Grand Rapids | Michigan | 49252 | — |
| Novartis Investigative SIte | Royal Oak | Michigan | 48073 | — |
| Novartis Investigative Site | Williamsburg | Michigan | 49690 | — |
| Novartis Investigative Site | Independence | Missouri | 64055 | — |
| Novartis Investigative Site | St Louis | Missouri | 63110 | — |
| Novartis Investigative Site | Toms River | New Jersey | 08755 | — |
| Novartis Investigative Site | Lynbrook | New York | 11563 | — |
| Novartis Investigative Site | Rochester | New York | 14620 | — |
| Novartis Investigative Site | Beachwood | Ohio | 44122 | — |
| Novartis Investigative Site | Cincinnati | Ohio | 45242 | — |
| Novartis Investigative Site | Cleveland | Ohio | 44195 | — |
| Novartis Investigative Site | Pittsburgh | Pennsylvania | 15213 | — |
| Novartis Investigative Site | West Mifflin | Pennsylvania | 15122 | — |
| Novartis Investigative Site | West Columbia | South Carolina | 29169 | — |
| Novartis Investigative Site | Rapid City | South Dakota | 57701 | — |
| Novartis Investigative Site | Kingsport | Tennessee | 37660 | — |
| Novartis Investigative Site | Knoxville | Tennessee | 37909 | — |
| Novartis Investigative Site | Austin | Texas | 78705 | — |
| Novartis Investigative Site | Houston | Texas | 77030 | — |
| Novartis Investigative Site | Fairfax | Virginia | 22031 | — |
| Novartis Investigative Site | Richmond | Virginia | 23226 | — |
| Novartis Investigative Site | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00436553, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 19, 2011 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00436553 live on ClinicalTrials.gov.